Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

(2018) Y Bareche et al.   ANNALS OF ONCOLOGY

Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer?

(2018) Sara Bravaccini et al.   BREAST CANCER RESEARCH AND TREATMENT

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

(2018) Michael J. Duffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

(2018) Ricardo L. B. Costa et al.   BREAST CANCER RESEARCH AND TREATMENT

The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity

(2018) Andrew B. Fielding et al.   ONCOGENE

Cell Cycle Control by PTEN

(2017) Andrew Brandmaier et al.   JOURNAL OF MOLECULAR BIOLOGY

A New Gene Expression Signature for Triple-Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy

(2017) Sandra K Santuario-Facio et al.   MOLECULAR MEDICINE

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer

(2017) Ayako Nakashoji et al.   Oncology Letters

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients

(2017) Yunbao Pan et al.   PLoS One

Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response

(2016) Gamal M Elnemr et al.   Asian Pacific Journal of Cancer Prevention

Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers

(2016) Amélie Fouqué et al.   Recent Patents on Anti-Cancer Drug Discovery

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

(2016) Silvia Darb-Esfahani et al.   Oncotarget

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

(2016) Daniela Massihnia et al.   Oncotarget

Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy

(2016) Wanyin Chen et al.   Stem Cells International

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma

(2015) L Rossi et al.   BRITISH JOURNAL OF CANCER

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications

(2015) Sherri Z. Millis et al.   Clinical Breast Cancer

The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

(2015) Rishil J. Kathawala et al.   DRUG RESISTANCE UPDATES

Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification

(2015) Fouzia Guestini et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis

(2015) Lin Yuan et al.   NATURE CELL BIOLOGY

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

(2015) MUYOU TIAN et al.   Oncology Letters

PTEN stabilizes TOP2A and regulates the DNA decatenation

(2015) Xi Kang et al.   Scientific Reports

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer

(2015) Francesca Collina et al.   Biomed Research International

Focus on PTEN regulation

(2015) Miriam Bermúdez Brito   Frontiers in Oncology

Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study

(2015) Zsuzsanna Varga et al.   PLoS One

Therapeutic Targeting of Cancers with Loss of PTEN Function

(2014) Lloye Dillon et al.   CURRENT DRUG TARGETS

BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy

(2014) Beata Biesaga et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

(2014) Kunpeng Wu et al.   World Journal of Surgical Oncology

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers

(2014) S. Lindsey Davis et al.   Therapeutic Advances in Medical Oncology

High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival

(2013) Akimitsu Yamada et al.   BREAST CANCER RESEARCH AND TREATMENT

Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype

(2013) Peeter Karihtala et al.   BREAST CANCER RESEARCH AND TREATMENT

Vimentin as a poor prognostic factor for triple-negative breast cancer

(2013) Nami Yamashita et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

(2013) Brian D Lehmann et al.   JOURNAL OF PATHOLOGY

Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer

(2013) Mevlude Inanc et al.   MEDICAL ONCOLOGY

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

(2013) P E Lønning et al.   ONCOGENE

Neoadjuvant Chemotherapy Induces Expression Levels of Breast Cancer Resistance Protein That Predict Disease-Free Survival in Breast Cancer

(2013) Baek Kim et al.   PLoS One

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment

(2012) Katerina Bouchalova et al.   BIOMEDICAL PAPERS-OLOMOUC

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy

(2012) Jiayu Wang et al.   BREAST CANCER RESEARCH AND TREATMENT

Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer

(2012) Jabed Iqbal et al.   HISTOPATHOLOGY

Prognostic influence of BCL2 expression in breast cancer

(2012) Ki-Tae Hwang et al.   INTERNATIONAL JOURNAL OF CANCER

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

(2012) Michail Ignatiadis et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

(2011) M. Martin et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors

(2011) Kareem Tawfik et al.   HUMAN PATHOLOGY

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   MOLECULAR CANCER THERAPEUTICS

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Post-translational regulation of PTEN

(2008) X Wang et al.   ONCOGENE